ID: MRFR/Pharma/1984-HCR | 84 Pages | Author: Rahul Gotadki | September 2023
Table of Content
1 Introduction
1.1 Definition
1.2 Scope of Study
1.3 Research Objective
1.4 Assumptions & Limitations
1.5 Market Structure:
2 Research Methodology
2.1 Research Process
2.2 Primary Research
2.3 Secondary Research
3 Market Dynamics
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Challenges
3.5 Macroeconomic Indicators
4 Market Factor Analysis
4.1 Porter’s Five Forces Model
4.1.1 Bargaining Power of suppliers
4.1.2 Bargaining Power of Customer
4.1.3 Intensity of Competitor’s
4.1.4 Threat of New Entrants
5 Middle East and Africa Human Vaccines Market, by Technology
5.1 Introduction
5.1.1 Attenuated
5.1.2 Inactivated
5.1.3 Toxoid
5.1.4 Conjugate and Subunit
5.1.5 Recombinant DNA
6 Middle East and Africa Human Vaccines Market, by Disease Indication
6.1 Introduction
6.1.1 Pneumococcal
6.1.2 Influenza
6.1.3 Hepatitis
6.1.4 Rotavirus
6.1.5 DTP
6.1.6 Polio
6.1.7 Others
7 Middle East and Africa Human Vaccines Market, by Type
7.1 Introduction
7.1.1 Prophylactic
7.1.2 Therapeutic
8 Middle East and Africa Human Vaccines Market, by Composition
8.1 Introduction
8.1.1 Mono vaccine and
8.1.2 Combination vaccines
9 Middle East and Africa Human Vaccines Market, by Route of Administration
9.1 Introduction
9.1.1 Oral
9.1.2 Injectible
9.1.3 Others
10 Middle East and Africa Human Vaccines Market, by End User
10.1 Introduction
10.1.1 Children
10.1.2 Adults
11 Middle East and Africa Human Vaccines Market, by Country
11.1 Introduction
11.1.2 UAE
11. 1.3 Egypt
11. 1.4 Saudi Arabia
11. 1.5 Kuwait
11. 1.6 Qatar
11. 1.7 Oman
12 Company Landscape
12.1 Introduction
12.1.1 Mergers Acquisitions
12.1.2 Collaborations
12.1.3 Release/New Product Launches
12.1.4 Other (Expansion, Updates, Partnership)
13 Company Profile
13.1 GlaxoSmithKline Plc.
13.1.1 Company Overview
13.1.2 Product/Business Segment Overview
13.1.3 Financials
13.1.4 Key Developments
13.1.5 SWOT Analysis
13.2 Merck & Co. Inc.
13.2.1 Overview
13.2.2 Product/Business Segment Overview
13.2.3 Financials
13.2.4 Key Developments
13.2.5 SWOT Analysis
13.3 Pfizer, Inc.
13.3.1 Overview
13.3.2 Product/Business Segment Overview
13.3.3 Financials
13.3.4 Key Developments
13.3.5 SWOT Analysis
13.4 Sanofi Pasteur, Inc.
13.4.1 Overview
13.4.2 Product/Business Segment Overview
13.4.3 Financials
13.4.4 Key Developments
13.4.5 SWOT Analysis
13.5 AstraZeneca Plc.
13.5.1 Overview
13.5.2 Product/Business Segment Overview
13.5.3 Financials
13.5.4 Key Developments
13.5.5 SWOT Analysis
13.6 Bharat Biotech
13.6.1 Overview
13.6.2 Product/Business Segment Overview
13.6.3 Financials
13.6.4 Key Developments
13.6.5 SWOT Analysis
13.7 Shenzhen Kangtai Biological Products
13.7.1 Overview
13.7.2 Product/Business Segment Overview
13.7.3 Financials
13.7.4 Key Developments
13.7.5 SWOT Analysis
13.8 Valeant Pharmaceuticals
13.8.1 Overview
13.8.2 Product/Business Segment Overview
13.8.3 Financials
13.8.4 Key Developments
13.8.5 SWOT Analysis
13.9 Emergent Biosolutions Inc.
13.9.1 Overview
13.9.2 Product/Business Segment Overview
13.9.3 Financials
13.9.4 Key Developments
13.9.5 SWOT Analysis
13.10 Astellas Pharma Inc.
13.10.1 Overview
13.10.2 Product/Business Segment Overview
13.10.3 Financials
13.10.4 Key Developments
13.10.5 SWOT Analysis
13.11 Panacea Biotec
13.11.1 Overview
13.11.2 Product/Business Segment Overview
13.11.3 Financials
13.11.4 Key Developments
13.11.5 SWOT Analysis
14 Others
15 Appendix
List of Tables
TABLE 1 MIDDLE EAST AND AFRICA HUMAN VACCINES MARKET, 2023-2030 (USD MILLION)
TABLE 2 MIDDLE EAST AND AFRICA HUMAN VACCINES MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
TABLE 3 MIDDLE EAST AND AFRICA HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2023-2030 (USD MILLION)
TABLE 4 MIDDLE EAST AND AFRICA HUMAN VACCINES MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 5 MIDDLE EAST AND AFRICA HUMAN VACCINES MARKET, BY COMPOSITION, 2023-2030 (USD MILLION)
TABLE 6 MIDDLE EAST AND AFRICA HUMAN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)
TABLE 7 MIDDLE EAST AND AFRICA HUMAN VACCINES MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 8 MIDDLE EAST AND AFRICA HUMAN VACCINES MARKET, BY REGION, 2023-2030 (USD MILLION)
List of Figures
FIGURE 1 RESEARCH PROCESS
FIGURE 2 PORTERS FIVE FORCES MODEL
FIGURE 3 MIDDLE EAST AND AFRICA HUMAN VACCINES MARKET, BY TECHNOLOGY
FIGURE 4 MIDDLE EAST AND AFRICA HUMAN VACCINES MARKET, BY DISEASE INDICATION
FIGURE 5 MIDDLE EAST AND AFRICA HUMAN VACCINES MARKET, BY TYPE
FIGURE 6 MIDDLE EAST AND AFRICA HUMAN VACCINES MARKET, BY COMPOSITION
FIGURE 7 MIDDLE EAST AND AFRICA HUMAN VACCINES MARKET, BY ROUTE OF ADMINISTRATION
FIGURE 8 MIDDLE EAST AND AFRICA HUMAN VACCINES MARKET, BY END USER
FIGURE 9 MIDDLE EAST AND AFRICA HUMAN VACCINES MARKET, BY REGION
FIGURE 10 MIDDLE EAST AND AFRICA HUMAN VACCINES MARKET: COMPANY SHARE ANALYSIS, 2020 (%)
Human Vaccines Market Segmentation
Vaccines Technology Outlook (USD Billion, 2018-2032)
Attenuated
Inactivated
Toxoid
Conjugate & Subunit
Recombinant DNA
Middle East and Africa Human Vaccines Route of Administration Outlook (USD Billion, 2018-2032)
Oral
Injectable
Other
Middle East and Africa Human Vaccines Type Outlook (USD Billion, 2018-2032)
Prophylactic
Therapeutic
Middle East and Africa Human Vaccines Disease Indication Outlook (USD Billion, 2018-2032)
Pneumococcal
Influenza
Hepatitis
Rotavirus
DTP
Polio
Others
Middle East and Africa Human Vaccines End User Outlook (USD Billion, 2018-2032)
Children
Adults
Middle East and Africa Human Vaccines Composition Outlook (USD Billion, 2018-2032)
Mono Vaccine
Combination Vaccine
Middle East and Africa Human Vaccines Regional Outlook (USD Billion, 2018-2032)
GCC Countries Outlook (USD Billion, 2018-2032)
GCC Countries Human Vaccines by Technology
Attenuated
Inactivated
Toxoid
Conjugate & Subunit
Recombinant DNA
GCC Countries Human Vaccines by Route of Administration
Oral
Injectable
Other
GCC Countries Human Vaccines by Type
Prophylactic
Therapeutic
GCC Countries Human Vaccines by Disease Indication
Pneumococcal
Influenza
Hepatitis
Rotavirus
DTP
Polio
Others
GCC Countries Human Vaccines by End User
Children
Adults
GCC Countries Human Vaccines by Composition
Mono Vaccine
Combination Vaccine
South Africa Outlook (USD Billion, 2018-2032)
South Africa Human Vaccines by Technology
Attenuated
Inactivated
Toxoid
Conjugate & Subunit
Recombinant DNA
South Africa Human Vaccines by Route of Administration
Oral
Injectable
Other
South Africa Human Vaccines by Type
Prophylactic
Therapeutic
South Africa Human Vaccines by Disease Indication
Pneumococcal
Influenza
Hepatitis
Rotavirus
DTP
Polio
Others
South Africa Human Vaccines by End User
Children
Adults
South Africa Human Vaccines by Composition
Mono Vaccine
Combination Vaccine
Rest of MEA Outlook (USD Billion, 2018-2032)
Rest of MEA Human Vaccines by Technology
Attenuated
Inactivated
Toxoid
Conjugate & Subunit
Recombinant DNA
Rest of MEA Human Vaccines by Route of Administration
Oral
Injectable
Other
Rest of MEA Human Vaccines by Type
Prophylactic
Therapeutic
Rest of MEA Human Vaccines by Disease Indication
Pneumococcal
Influenza
Hepatitis
Rotavirus
DTP
Polio
Others
Rest of MEA Human Vaccines by End User
Children
Adults
Rest of MEA Human Vaccines by Composition
Mono Vaccine
Combination Vaccine